Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute kidney injury

Short-term statin therapy for prevention of contrast-induced AKI

Nature Reviews Nephrology volume 10, pages 8–9 (2014)Cite this article

Subjects

Two recent studies suggest that periprocedural statin administration can prevent contrast-induced acute kidney injury in cardiac patients undergoing percutaneous coronary intervention and in renal patients undergoing angiography, with or without intervention. These studies support the routine administration of potent statins before contrast media infusion in these vulnerable patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. McCullough, P. A. et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 98, 5K–13K (2006).

    Article  CAS  Google Scholar 

  2. Chang, C. F. & Lin, C. C. Current concepts of contrast-induced nephropathy: a brief review. J. Chin. Med. Assoc. http://dx.doi.org/10.1016/j.jcma.2013.08.011.

  3. Han, Y. et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09.017.

  4. Leoncini, M. et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study). J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.04.105.

  5. Ho, J. E. et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the treating to new targets [TNT] study). Am. J. Cardiol. 109, 1761–1766 (2012).

    Article  CAS  Google Scholar 

  6. Athyros, V. G., Karagiannis, A., Katsiki, N. & Mikhailidis, D. P. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. Am. J. Cardiol. 110, 763 (2012).

    Article  Google Scholar 

  7. Quintavalle, C. et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 126, 3008–3016 (2012).

    Article  CAS  Google Scholar 

  8. Patti G. et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial). Am. J. Cardiol. 108, 1–7 (2011).

    Article  CAS  Google Scholar 

  9. McCullough, P. A. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 51, 1419–1428 (2008).

    Article  Google Scholar 

  10. Pasceri, V. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 110, 674–678 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital, Royal Free and University College School of Medicine, Pond Street, London, NW3 2QG, UK

    Dimitri P. Mikhailidis

  2. Second Propedeutic Department of Internal Medicine, Atherosclerosis and Metabolic Syndrome Outpatient Units, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 15 Marmara Street, Thessaloniki, 55132, Greece

    Vasilios G. Athyros

Authors
  1. Dimitri P. Mikhailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vasilios G. Athyros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitri P. Mikhailidis.

Ethics declarations

Competing interests

D. P. Mikhailidis has given talks, attended conferences and participated in trials and advisory boards sponsored by MSD and Genzyme. V. G. Athyros declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikhailidis, D., Athyros, V. Short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol 10, 8–9 (2014). https://doi.org/10.1038/nrneph.2013.249

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2013.249

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing